Mergers & Acquisitions ·
On August 19, 2026, Apimeds Pharmaceuticals US, Inc. entered into an Assignment and Transfer Agreement with FreeT…
APUSApimeds Pharmaceuticals US, Inc.
On August 19, 2026, Apimeds Pharmaceuticals US, Inc. entered into an Assignment and Transfer Agreement with FreeT Inc., acquiring specific rights to its lead asset, Apitox. The transaction grants the company 100% of rights for the Korean medicine clinic market in South Korea, a 25% royalty entitlement on U.S. economic proceeds from development or commercialization, and a 25% revenue participation right on net proceeds from overseas licensing agreements. Additionally, Apimeds secured rights to quarterly clinical progress updates and certain manufacturing data benefits. The company confirmed these assigned rights are free of prior encumbrances and assumes no pre-existing liabilities of FreeT. This strategic acquisition expands the company's intellectual property portfolio and potential revenue streams for its proprietary bee venom-based therapeutic candidate. Apimeds Pharmaceuticals US, Inc. operates in the biotechnology industry, focusing on the development of novel therapeutics derived from apitoxin.